NCT04287608

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for conjunctivitis events and its effectiveness.

Conditions

• Conjunctivitis
• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	dupilumab	No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.

Timeline

• Start date: 2021-03-10
• Primary completion: 2023-03-29
• Completion: 2023-03-29
• First posted: 2020-02-27
• Last updated: 2023-04-28

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study